The Alexandra Whiteley Lab at CU Boulder discovered a new potential biological driver of ALS that holds promise for a new method of treating this fatal disease. Endios Bio is developing novel therapeutics targeting this underlying mechancism, and working to move these discoveries into clinical trials for ALS patients.
A fatal disease
80% of ALS patients die within 2-5 years after diagnosis
30,000 Americans
5,000 new cases diagnosed each year, affecting people ages 40-70
No cure at present
Only two current treatments, which don't slow disease
Support our Mission
Learn more about our science:
Whether you are a researcher looking to collaborate, or interested in funding our journey, let's set up a time to talk.
